CommercialDocumentationMedium impact
08.01.73j, Filgrastim (Neupogen®) and Related Biosimilars, and tbo-filgrastim (Granix®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
The insurance policy for Filgrastim (Neupogen®) and related biosimilars, and tbo-filgrastim (Granix®) has been updated with new medical necessity criteria and medical coding requirements. This affects how these medications must be documented and billed for coverage approval.
Action Required
By April 20, 2026: Billing team must review and update medical necessity documentation requirements for Filgrastim (Neupogen®), related biosimilars, and tbo-filgrastim (Granix®) claims. Update billing system with new medical coding requirements. Ensure providers document appropriate medical necessity criteria before prescribing. Claims without proper documentation may be denied.